依库珠单抗治疗儿童产志贺毒素大肠杆菌相关溶血性尿毒症综合征的匹配队列研究结局
两组均无死亡,1个月内血液学及肾脏参数演变无差异,12个月随访时肾脏结局无显著差异;依库珠单抗组随访期肾外后遗症更常见,治疗看似安全,但获益未能确立,需随机对照试验验证。
要点
- 依库珠单抗治疗STEC-HUS患儿与未治疗匹配对照组相比,肾脏结局无显著差异。
- 依库珠单抗组随访期肾外后遗症更常见。
- 依库珠单抗在该人群看似安全,但获益未确立,需随机对照试验。
核心结论
- 基于本研究发现,依库珠单抗对STEC-HUS患儿肾脏及肾外结局的获益未能确立。
- 依库珠单抗治疗在STEC-HUS患儿中看似安全。
- 观察性设计和小样本量不足以评估疗效与安全性,需随机对照试验确定依库珠单抗在该适应症中的疗效。
研究设计与样本
- 单中心匹配队列研究,回顾性收集诊断为STEC-HUS的患儿病历资料。
主要发现
- 两组患者均存活。
- HUS起病1个月内,两组血液学及肾脏参数演变无差异。
- 随访12个月时,两组肾脏结局无显著差异。
- 末次随访时,依库珠单抗组肾小球滤过率下降的患病率为27%,对照组为38%,差异无统计学意义;蛋白尿及高血压患病率同样无显著差异。
- 接受依库珠单抗的患儿在随访期间肾外后遗症更常见。
临床怎么用
- 当前证据不支持常规使用依库珠单抗治疗儿童STEC-HUS,需个体化评估并优先考虑随机对照试验证据。
局限性
- 观察性设计和小样本量不足以最佳评估疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment with eculizumab in Shiga toxin-associated haemolytic and uraemic syndrome (STEC-HUS) remains controversial despite its increasing utilization. The aim of our study was to evaluate the outcomes of children treated with eculizumab for STEC-HUS in a single-centre matched cohort study. METHODS: Data were retrospectively collected from medical records of children diagnosed with STEC-HUS. The outcomes of patients treated with eculizumab for STEC-HUS were compared with those of a control group of untreated patients matched for age, sex and severity of acute kidney injury with a 1:2 matching scheme. RESULTS: Eighteen children (median age 40.6 months) with STEC-HUS treated with eculizumab were compared with 36 matched control patients (median age 36.4 months) who did not receive eculizumab. All patients survived in the two groups. Within 1 month of HUS onset, the evolution of haematological and renal parameters did not differ between the two groups. At 12 months of follow-up, renal outcome was not significantly different between the two groups. At the last follow-up, the prevalence of decreased glomerular filtration rate in the eculizumab group (27%) was not statistically different from that in controls (38%), as was the prevalence of proteinuria and high blood pressure. Children who received eculizumab more often had extrarenal sequelae during follow-up. Eculizumab treatment appeared to be safe in children with STEC-HUS. CONCLUSION: The benefit of eculizumab on renal and extrarenal outcomes in STEC-HUS could not be established based on our findings. However, efficacy and safety are not best assessed by the observational design and small sample size of our study. Randomized controlled trials are thus required to determine the efficacy of eculizumab in this indication.
引用
- Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, et al. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant. 2020. PMID: 31411695. doi:10.1093/ndt/gfz158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。